FIGURE 4

FIGURE 4

TNO155 and lorlatinib treatment delays tumor growth in ALK-mutant mouse xenografts. A, Tumor volumes of Kelly xenografts treated orally with high- or low-dose regimens of TNO155, lorlatinib, combination treatment (Combo), or vehicle control for 4 weeks. Tumor growth (B) and Kaplan–Meier survival curves (C) of Kelly xenografts treated with high-dose vehicle (n = 5), TNO155 (n = 4), lorlatinib (n = 5), or combination (Combo, n = 4) treatments. Tumor growth (D) and Kaplan–Meier survival curves (E) of Kelly xenografts treated with low-dose vehicle (n = 3), TNO155 (n = 3), lorlatinib (n = 3), or combination (Combo, n = 4) treatments F, Protein expression analyses of tumor lysates treated with vehicle control (n = 3), TNO155 (7.5 mg/kg twice per day, n = 3), lorlatinib (1 mg/kg twice per day, n = 3), or combination (Combo, n = 3) for 20 days. *, P < 0.05; **, P < 0.01; n.s., not significant.